Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Dec;37(6):1128-35.
doi: 10.1007/s11096-015-0174-4. Epub 2015 Aug 5.

Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands

Affiliations
Observational Study

Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands

Susan Hanemaaijer et al. Int J Clin Pharm. 2015 Dec.

Abstract

Background: Non-vitamin K oral anticoagulants (NOACs) became available in the Netherlands in 2008, providing another antithrombotic treatment besides vitamin K antagonists (VKAs) and antiplatelet agents (APAs).

Objective: To describe the patterns of antithrombotic drug use between 2008 and 2013 by examination of dispensing data form community pharmacies in the Netherlands; to determine the concomitant use of NOACs with VKAs and APAs and switching between the drug classes; and to compare adherence to NOACs with adherence to APAs.

Setting: An observational retrospective study was conducted using routinely collected dispensing data from Dutch community pharmacies.

Methods: For each calendar year, the numbers of NOAC, VKA, and APA users were calculated. Adherence was determined for NOACs and APAs by the percentage of days covered by medication (PDC). Information on the prescribed daily dose of VKAs was unavailable.

Main outcome measures: Comparison of age, sex, and co-medications of users of the three drug classes; concomitant use of different antithrombotic drug classes and switching between these in each year; and mean PDC and percentages of all users with a PDC above 80 %.

Results: NOAC use increased during the study period to 29,687 users in 2013. In that year there were 484,024 VKA users and 1313,032 APA users. Compared with users of VKAs, NOAC users were slightly younger and more frequently used antiarrhythmic drugs and beta blockers as co-medications. Substantial numbers of patients were dispensed potentially harmful combinations in 2013: 820 subjects were dispensed NOACs together with VKAs, and 684 subjects were dispensed NOACs, VKAs, and APAs concomitantly. Mean adherence to NOACs was 84.2 % compared with 87.3 % to APA. One in four NOAC users had a PDC lower than 80 % compared with one in five APA users.

Conclusion: Our findings show increasing use of NOACs by outpatients. The number of patients taking potentially harmful combinations of antithrombotic drugs was substantial. Adherence to NOACs in daily practice may be suboptimal to prevent thrombotic events.

Keywords: Adherence; DOACs; Drug use patterns; NOACs; Netherlands; Non-vitamin K oral anticoagulants.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Annual increase in the total number of for short- and long-term NOAC users between 2008 and 2013. Annual numbers based on community pharmacies with data available were standardised for the total number of Dutch community pharmacies per year (see annual numbers of pharmacies with data available and the total number in the Netherlands at the bottom of Table 2)

Similar articles

Cited by

References

    1. Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26:103–114. doi: 10.1016/j.beha.2013.07.009. - DOI - PubMed
    1. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden A, van Schaik R, Hofman A, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet. 2009;18(19):3758–3768. doi: 10.1093/hmg/ddp309. - DOI - PubMed
    1. Teichert M, van Schaik R, Hofman A, Uitterlinden A, de Smet P, Stricker B, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther. 2009;85(4):379–386. doi: 10.1038/clpt.2008.294. - DOI - PubMed
    1. Bauer K. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal. Stroke. 2013;44:S38–S40. doi: 10.1161/STROKEAHA.111.000387. - DOI - PubMed
    1. Baker W, Cios D, Sander S, Coleman C. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244–252. - PMC - PubMed

Publication types

LinkOut - more resources